Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study Toshio ShimizuKazuhiko NakagawaMasayuki Takeda Research Open access 04 November 2022 Pages: 1 - 12
The influence of verapamil on the pharmacokinetics of the pan-HER tyrosine kinase inhibitor neratinib in rats: the role of P-glycoprotein-mediated efflux Defei QiYuanyuan DouHua Sun Research 04 November 2022 Pages: 13 - 24
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors Shubham PantTomislav DragovichScott Kopetz Research 04 November 2022 Pages: 25 - 34
Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence Yusuke ShimaYuki SatoKeisuke Tomii Research 05 November 2022 Pages: 35 - 43
Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE) Kun QianQi-Rui ChenYi Zhang PHASE II STUDIES 10 November 2022 Pages: 44 - 52
A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors Neeltje SteeghsMelinda PruisXiaofei Zhou Research Open access 21 November 2022 Pages: 53 - 59
Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions Zhengzhi LiuZhongnan XuHaimiao Yang Research 28 November 2022 Pages: 60 - 69
An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer Jayanthi VijayakumarTufia HaddadDouglas Yee PHASE II STUDIES Open access 28 November 2022 Pages: 70 - 75
A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer Naminatsu TakaharaYousuke NakaiKazuhiko Koike Research Open access 02 December 2022 Pages: 76 - 85
Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China Helei HouYongjie WangXiaochun Zhang Research 12 December 2022 Pages: 86 - 92
A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors Victor MorenoRuth PeretsEmiliano Calvo Research 20 December 2022 Pages: 93 - 104
DGG-300273, a novel WNT/β-catenin inhibitor, induces apoptotic cell death by activating ROS-BIM signaling in a Wnt-dependent manner in colon cancer cells Do Yeon KimYea Seong RyuDong-Hoon Jin Research 20 December 2022 Pages: 105 - 114
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma Hiroya ManakaSatoshi IgawaKatsuhiko Naoki Research 12 January 2023 Pages: 115 - 121
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study Emi IshikawaYuta YokoyamaTomonori Nakamura Research Open access 13 January 2023 Pages: 122 - 133
Viscosalactone B, a natural LSD1 inhibitor, inhibits proliferation in vitro and in vivo against prostate cancer cells Gaobo YanHongyan ZhangQifan Lv Research 24 January 2023 Pages: 134 - 141
Novel pentacyclic derivatives and benzylidenes of the progesterone series cause anti-estrogenic and antiproliferative effects and induce apoptosis in breast cancer cells Alexander M. ScherbakovSvetlana K. VorontsovaValerii Z. Shirinian Research 25 January 2023 Pages: 142 - 152
Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotides Alexander S. VedenkinSergey V. StovbunDmitry A. Kuznetsov Research 07 February 2023 Pages: 153 - 161
A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma Mingzhen ZhouSihui ZhuJie Shen Research 10 February 2023 Pages: 162 - 167
Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma Fumihiko KinoshitaYuka OkuTatsuro Okamoto Case Study 04 November 2022 Pages: 168 - 172
Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials Shigemasa TakamizawaYuki KatsuyaShigenobu Suzuki Brief Report Open access 05 December 2022 Pages: 173 - 181
Corrections to: Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma Peng YuanJinhua SongBaoan Chen Correction 13 December 2022 Pages: 182 - 182